Meta Information

ID:teriparatide

Name:Teriparatide

Schema Version:1.5

Alternate Names

• Forteo

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:

1000

High Cost:

4000

Cost Type:

monthly

Description:

Prescription medication cost, often covered by insurance for severe osteoporosis.

Summary

Teriparatide is a recombinant form of human parathyroid hormone that stimulates new bone formation by preferentially activating osteoblasts. Its primary healthspan relevance is the significant reduction of fracture risk in individuals with severe osteoporosis, a condition that dramatically increases morbidity, mortality, and loss of independence with age.

Purpose

Recombinant parathyroid hormone that builds new bone to prevent fractures.

Card Summary

A prescription injectable that reverses osteoporosis by stimulating new bone formation.

Drug Class

parathyroid-hormone-analogs

Drugs In Class

Empty Array

Impact

Score:

5.5

Justification:

Highly effective for reversing severe osteoporosis, a major age-related morbidity driver.

Evidence

Grade:

A

Score:

9.5

Justification:

Extensive, high-quality human RCTs and meta-analyses for treating severe osteoporosis.

Safety

Score:

6.5

Justification:

Prescription drug with a black box warning for osteosarcoma risk; requires medical supervision.

Flags

• Black box warning for a potential increased risk of osteosarcoma.
• Lifetime use is typically limited to a cumulative total of 24 months.
• Requires a prescription and ongoing medical supervision.
• May cause hypercalcemia, dizziness, nausea, and leg cramps.
• Contraindicated in patients with Paget's disease or prior skeletal radiation therapy.

Verdict

A powerful, targeted tool for severe osteoporosis, not a general longevity drug.

Created

2026-04-26T18:31:14.197422Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:

subcutaneous_injection

Scope:

• systemic

Indication

Focus:

healthspan

Description:

Teriparatide is a recombinant form of human parathyroid hormone that stimulates new bone formation by preferentially activating osteoblasts. Its primary healthspan relevance is the significant reducti...

Typical Protocol

• 20 mcg administered daily via subcutaneous injection, typically for a lifetime maximum of 2 years.